Presbia PLC (NASDAQ:LENS) Upgraded by Zacks Investment Research to Hold

Presbia PLC (NASDAQ:LENS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, July 25th.

According to Zacks, “Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company’s product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. “

Other research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Presbia PLC in a research report on Tuesday, May 23rd. Rodman & Renshaw decreased their price objective on shares of Presbia PLC from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, May 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $12.00.

Shares of Presbia PLC (LENS) opened at 2.70 on Tuesday. Presbia PLC has a 52 week low of $1.86 and a 52 week high of $5.15. The firm’s market capitalization is $45.78 million. The stock has a 50 day moving average price of $2.32 and a 200-day moving average price of $2.82.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was published by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at [[permalink]].

An institutional investor recently raised its position in Presbia PLC stock. FMR LLC increased its position in shares of Presbia PLC (NASDAQ:LENS) by 0.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,568,278 shares of the medical instruments supplier’s stock after buying an additional 13,375 shares during the period. FMR LLC owned 15.15% of Presbia PLC worth $5,856,000 as of its most recent filing with the SEC. Institutional investors own 19.58% of the company’s stock.

Presbia PLC Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

Get a free copy of the Zacks research report on Presbia PLC (LENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com